Tag: Hormone Replacement Therapy

Hormone replacement therapy also tied to elevated gastrointestinal symptoms and diagnostic testing

Decreases seen for women aged younger than 52 years, 52 to <65 years, and 65 years and older, and for Hispanic, non-Hispanic Black, non-Hispanic White women

Rates declined and remained low for women aged 45 to 49, 50 to 54, and 55 to 59 years

Biological aging discrepancy mediated the association between HT and decreased mortality

Hormone therapy no aid for cardiovascular disease prevention, and calcium/vitamin D supplementation no aid for universal fracture prevention

Hormone therapy use linked to risk reductions in mortality

Authors say more studies are needed to understand ideal timing window for treatment initiation

Biochemical recurrence does not meet the criteria to be a reliable surrogate endpoint for overall survival

Significant direct association seen between estrogen use, progestogen use, combined hormone therapy with gastroesophageal reflux disease

Higher hazard ratios noted with increasing duration of use; increased risk seen for those receiving treatment at age 55 years or younger